Laurynas Mockeliunas

Laurynas Mockeliunas

Auto-generated profile, based on publicly available information

Laurynas Mockeliunas

Department of Pharmaceutical Biosciences, Uppsala University, 751 24 Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LKLina Keutzer
Lina Keutzer
LMLaurynas Mockeliunas
Laurynas Mockeliunas
MSMarieke Sturkenboom
Marieke Sturkenboom
MBMathieu Bolhuis
Mathieu Bolhuis
OAOnno W. Akkerman
Onno W. Akkerman
Ulrika SH SimonssonUlrika SH Simonsson
Ulrika SH Simonsson
Long-term usage of linezolid can result in adverse events such as peripheral neuropathy, anemia and thrombocytopenia. Therapeutic drug monitoring data from 75 drug-resistant tuberculosis patients treated with linezolid were analyzed using a time-to-event (TTE) approach for peripheral neuropathy and anemia and indirect response modelling for thrombocytopenia. Different time-varying linezolid pharmacokinetic exposure indices (AUC0–24h,ss, Cav, Cmax and Cmin) and patient characteristics were investigated as risk factors. A treatment duration shorter than 3 months was considered dropout and was modelled using a TTE approach. An exposure–response relationship between linezolid Cmin and both peripheral neuropathy and anemia was found. The exposure index which best described the development of thrombocytopenia was AUC0–24h. The final TTE dropout model indicated an association between linezolid Cmin and dropout. New safety targets for each adverse event were proposed which can be used for individualized linezolid dosing. According to the model predictions at 6 months of treatment, a Cmin of 0.11 mg/L and 1.4 mg/L should not be exceeded to keep the cumulative probability to develop anemia and peripheral neuropathy below 20%. The AUC0–24h should be below 111 h·mg/L or 270 h·mg/L to prevent thrombocytopenia and severe thrombocytopenia, respectively. A clinical utility assessment showed that the currently recommended dose of 600 mg once daily is safer compared to a 300 mg BID dosing strategy considering all four safety endpoints.

10 July 2023 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
Rob van WijkRob van Wijk
Rob van Wijk
LMLaurynas Mockeliunas
Laurynas Mockeliunas
CUCaryn M. Upton
Caryn M. Upton
JPJonathan Peter
Jonathan Peter
ADAndreas H. Diacon
Andreas H. Diacon
Ulrika SH SimonssonUlrika SH Simonsson
Ulrika SH Simonsson
Respiratory tract infections (RTIs) are a burden to global health, but their characterization is complicated by the influence of seasonality on incidence and severity. The Re-BCG-CoV-19 trial (NCT04379336) assessed BCG (re)vaccination for protection from coronavirus disease 2019 (COVID-19) and recorded 958 RTIs in 574 individuals followed over 1 year. We characterized the probability of RTI occurrence and severity using a Markov model with health scores (HSs) for four states of symptom severity. Covariate analysis on the transition probability between HSs explored the influence of demographics, medical history, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), or influenza vaccinations, which became available during the trial, SARS-CoV-2 serology, and epidemiology-informed seasonal influence of infection pressure represented as regional COVID-19 pandemic waves, as well as BCG (re)vaccination. The infection pressure reflecting the pandemic waves increased the risk of RTI symptom development, whereas the presence of SARS-CoV-2 antibodies protected against RTI symptom development and increased the probability of symptom relief. Higher probability of symptom relief was also found in participants with African ethnicity and with male biological gender. SARS-CoV-2 or influenza vaccination reduced the probability of transitioning from mild to healthy symptoms. Model diagnostics over calendar-time indicated that COVID-19 cases were under-reported during the first wave by an estimated 2.76-fold. This trial was performed during the initial phase of the COVID-19 pandemic in South Africa and the results reflect that situation. Using this unique clinical dataset of prospectively studied RTIs over the course of 1 year, our Markov Chain model was able to capture risk factors for RTI development and severity, including epidemiology-informed infection pressure.

19 March 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
LMLaurynas Mockeliunas
Laurynas Mockeliunas
Rob van WijkRob van Wijk
Rob van Wijk
CUCaryn Megan Upton
Caryn Megan Upton
JPJonathan Peter
Jonathan Peter
ADAndreas H. Diacon
Andreas H. Diacon
Ulrika SH SimonssonUlrika SH Simonsson
Ulrika SH Simonsson
(1) Background: Some individuals are more susceptible to developing respiratory tract infections (RTIs) or coronavirus disease (COVID-19) than others. The aim of this work was to identify risk factors for symptomatic RTIs including COVID-19 and symptomatic COVID-19 during the coronavirus pandemic by using infection incidence, participant baseline, and regional COVID-19 burden data. (2) Methods: Data from a prospective study of 1000 frontline healthcare workers randomized to Bacillus Calmette–Guérin vaccination or placebo, and followed for one year, was analyzed. Parametric time-to-event analysis was performed to identify the risk factors associated with (a) non-specific symptomatic respiratory tract infections including COVID-19 (RTIs+COVID-19) and (b) symptomatic RTIs confirmed as COVID-19 using a polymerase chain reaction or antigen test (COVID-19). (3) Results: Job description of doctor or nurse (median hazard ratio [HR] 1.541 and 95% confidence interval [CI] 1.299–1.822), the reported COVID-19 burden (median HR 1.361 and 95% CI 1.260–1.469 for 1.4 COVID-19 cases per 10,000 capita), or a BMI > 30 kg/m2 (median HR 1.238 and 95% CI 1.132–1.336 for BMI of 35.4 kg/m2) increased the probability of RTIs+COVID-19, while positive SARS-CoV-2 serology at enrollment (median HR 0.583 and 95% CI 0.449–0.764) had the opposite effect. The reported COVID-19 burden (median HR 2.372 and 95% CI 2.116–2.662 for 1.4 COVID-19 cases per 10,000 capita) and a job description of doctor or nurse (median HR 1.679 and 95% CI 1.253–2.256) increased the probability of developing COVID-19, while smoking (median HR 0.428 and 95% CI 0.284–0.648) and positive SARS-CoV-2 serology at enrollment (median HR 0.076 and 95% CI 0.026–0.212) decreased it. (4) Conclusions: Nurses and doctors with obesity had the highest probability of developing RTIs including COVID-19. Non-smoking nurses and doctors had the highest probability of developing COVID-19 specifically. The reported COVID-19 burden increased the event probability, while positive SARS-CoV-2 IgG serology at enrollment decreased the probability of RTIs including COVID-19, and COVID-19 specifically.

17 December 2023 in BMJ Global Health
Verified
Conference Paper
Open access
PDF file
CUCaryn Megan Upton
Caryn Megan Upton
VJVeronique De Jager
Veronique De Jager
USUlrika Simonsson
Ulrika Simonsson
LMLaurynas Mockeliunas
Laurynas Mockeliunas
TMThabo Mabuka
Thabo Mabuka
ADAndreas Diacon
Andreas Diacon
Background Repurposing established antibiotics for TB has been successful, notably for fluoroquinolones, linezolid, and clofazimine. Meropenem co-administered with amoxicillin/clavulanate (A/Clav) demonstrated early bactericidal activity (EBA) in clinical trials (Diacon 2016; de Jager 2020; de Jager 2022). This study evaluated different regimens of carbapenems, A/Clav, and rifampicin, alone or in combinations. Methods This phase 2a, open-label, randomized trial recruited 132 HIV-negative adults with newly diagnosed, smear-positive, rifampicin-susceptible pulmonary TB. Participants received 14 days of treatment in one of 8 experimental arms, or standard-of-care (HRZE). EBA was determined with mixed effects modelling and reported as change in time (hours) to sputum culture positivity (TTP0-14) of samples collected overnight with 95% confidence intervals. Adverse events (AE) were assessed daily. Results A/Clav 2x1000/62.5mg orally twice daily showed no activity. TTP0-14 of other drugs in combination with A/Clav was, for meropenem 6g over 6 hours(6Mero6): 58.02 hours (18.72–192.92), meropenem 6g over 1 hour(6Mero1): 58.13 hours (27.26–121.83), meropenem 3g over 1 hour twice daily(3x2Mero): 60.07 hours (19.89–884.71), and meropenem 4g over 1 hour(4Mero1): 35.28 hours (25.31–84.74). Ertapenem 1g daily intravenously (ErtaIV) or intramuscularly (ErtaIM) was not active. The activity of rifampicin 35mg/kg daily plus A/Clav was 136.92 hours (103.21–400.64) and HRZE 134.30 hours (106.28–160.23). In 58 participants, 111 adverse events were reported. Most commonly diarrhoea (15 participants: four ErtaIM, three ErtaIV, four 6Mero6, two rifampicin, one each A/Clav and HRZE), injection site reactions (six participants: four ErtaIM, one each 6Mero6 and 3x2Mero), and raised transaminases (four participants: A/Clav, ErtaIM, Erta IV, rifampicin). Three SAEs occurred (pneumonia in ErtaIV, haemoptysis in rifampicin and 6Mero1) unrelated to treatment. Conclusion Rifampicin-based treatments showed the highest EBA. A/Clav and meropenem given at 6g per day, in single or divided doses, had higher EBA than lower doses, and shorter infusions were better tolerated. Ertapenem-based treatments and A/Clav alone showed no anti-TB activity. Funding: EDCTP 733079-H2020-SC1-2016-RTD

2 June 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
VJVeronique de Jager
Veronique de Jager
LMLaurynas Mockeliunas
Laurynas Mockeliunas
HYHuifang You
Huifang You
USUlrika S H Simonsson
Ulrika S H Simonsson
TCTarryn Collings
Tarryn Collings
KDKelly E Dooley
Kelly E Dooley
Background: In vitro, meropenem is shown to restore the activity of rifampicin in rifampicin-resistant Mycobacterium tuberculosis strains. This phase 2a trial aimed to determine if addition of rifampicin increases the early bactericidal activity (EBA) of meropenem plus amoxicillin/clavulanate in patients with rifampicin-resistant tuberculosis (RR-TB). Methods: Individuals with RR-TB were randomized to either 2 g meropenem infusion 3 times daily plus amoxicillin/clavulanate 500 mg/125 mg orally 3 times daily with 20 mg/kg rifampicin orally once daily (M-AC-R arm) or the same treatment without rifampicin (M-AC). Sputum samples were collected at baseline and throughout the 14-day treatment. Colony-forming unit (CFU) and time-to-positivity (TTP) data were analyzed using nonlinear mixed-effects modeling. Plasma samples at day 13 were used to derive rifampicin and meropenem pharmacokinetic parameters using noncompartmental analysis. Rifampicin minimum inhibitory concentrations (MICs) were determined from baseline sputum isolates with and without meropenem. Results: Of the 52 participants enrolled, 38 participants completed the trial. The majority (67%) were male, and the median age was 37 years. The median (95% prediction interval) predicted 14-day EBA in CFU was 1.33 (−0.15 to 3.64) and 1.20 (0.05–2.66) log10 CFU/mL, and TTP increased by 0.220 (0.098–0.551) and 0.216 (0.126–0.505) log10 hours for the M-AC-R and M-AC arms, respectively. No statistically significant difference was found between the 2 arms. Meropenem pharmacokinetics were similar in both arms, and rifampicin MICs were not meaningfully reduced by meropenem. Conclusions: Adding rifampicin to meropenem plus amoxicillin/clavulanate did not enhance short-term antibacterial activity in patients with RR-TB.